391 related articles for article (PubMed ID: 38280996)
1. Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells.
Huang CH; Yang TT; Lin KI
J Biomed Sci; 2024 Jan; 31(1):16. PubMed ID: 38280996
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new small ubiquitin-like modifier (SUMO)-interacting motif in the E3 ligase PIASy.
Kaur K; Park H; Pandey N; Azuma Y; De Guzman RN
J Biol Chem; 2017 Jun; 292(24):10230-10238. PubMed ID: 28455449
[TBL] [Abstract][Full Text] [Related]
3. Structural insights into the regulation of the human E2∼SUMO conjugate through analysis of its stable mimetic.
Goffinont S; Coste F; Prieu-Serandon P; Mance L; Gaudon V; Garnier N; Castaing B; Suskiewicz MJ
J Biol Chem; 2023 Jul; 299(7):104870. PubMed ID: 37247759
[TBL] [Abstract][Full Text] [Related]
4. E2-mediated small ubiquitin-like modifier (SUMO) modification of thymine DNA glycosylase is efficient but not selective for the enzyme-product complex.
Coey CT; Fitzgerald ME; Maiti A; Reiter KH; Guzzo CM; Matunis MJ; Drohat AC
J Biol Chem; 2014 May; 289(22):15810-9. PubMed ID: 24753249
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
[TBL] [Abstract][Full Text] [Related]
6. SUMO: From Bench to Bedside.
Chang HM; Yeh ETH
Physiol Rev; 2020 Oct; 100(4):1599-1619. PubMed ID: 32666886
[TBL] [Abstract][Full Text] [Related]
7. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
[TBL] [Abstract][Full Text] [Related]
8. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
9. The SUMO components in rheumatoid arthritis.
Wu Q; Jiang Y; You C
Rheumatology (Oxford); 2022 Nov; 61(12):4619-4630. PubMed ID: 35595244
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms in SUMO conjugation.
Varejão N; Lascorz J; Li Y; Reverter D
Biochem Soc Trans; 2020 Feb; 48(1):123-135. PubMed ID: 31872228
[TBL] [Abstract][Full Text] [Related]
11. Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9.
Subramaniam S; Mealer RG; Sixt KM; Barrow RK; Usiello A; Snyder SH
J Biol Chem; 2010 Jul; 285(27):20428-32. PubMed ID: 20424159
[TBL] [Abstract][Full Text] [Related]
12. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
[TBL] [Abstract][Full Text] [Related]
13. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
14. Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation.
Karaca E; Tozluoğlu M; Nussinov R; Haliloğlu T
J Mol Biol; 2011 Mar; 406(4):620-30. PubMed ID: 21216249
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
16. Rhes, a striatal enriched protein, regulates post-translational small-ubiquitin-like-modifier (SUMO) modification of nuclear proteins and alters gene expression.
Rivera O; Sharma M; Dagar S; Shahani N; Ramĺrez-Jarquĺn UN; Crynen G; Karunadharma P; McManus F; Bonneil E; Pierre T; Subramaniam S
Cell Mol Life Sci; 2024 Apr; 81(1):169. PubMed ID: 38589732
[TBL] [Abstract][Full Text] [Related]
17. Dynamin interacts with members of the sumoylation machinery.
Mishra RK; Jatiani SS; Kumar A; Simhadri VR; Hosur RV; Mittal R
J Biol Chem; 2004 Jul; 279(30):31445-54. PubMed ID: 15123615
[TBL] [Abstract][Full Text] [Related]
18. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
19. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion.
Kim ET; Kim KK; Matunis MJ; Ahn JH
Biochem Biophys Res Commun; 2009 Oct; 388(1):41-5. PubMed ID: 19635459
[TBL] [Abstract][Full Text] [Related]
20. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
